Effect of supplementation in treatment of schizophrenia patients
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT2017072333551N2
- Lead Sponsor
- Vice chancellor for research, Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Diagnosed with schizophrenia using DSM-IV-TR criteria
PANSS score of 55 or greater
Treated with chlorpromazine (300–1000mg/day, except clozapine) and agents anti-cholinergic (Trihexyphenidyl, 4–8 mg/day) during the last 6 months
Aged 25–65 years old
Disease duration of at least two years
Exclusion Criteria
Mental retardation
Substance or alcohol addiction (except caffeine or nicotine) with in the last 6 months of screening
A score of=14 on a 17-item Hamilton Depression Rating Scale or a score of =4 on PANSS (depression item)
Under treatment with lithium, carbamazepine and sodium valproic acid
Existing chronic and acute medical illness
Lactation or pregnancy
The use of anti-depressants including MAO, TCA, SSRI in the last 6 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive and Negative Syndrome Scale(PANSS). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical Examination.
- Secondary Outcome Measures
Name Time Method